The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is:
Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla to the placebo axilla to see if there is a difference in self-perceived odor and microbiome.
Participants will:
* be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla)
* self assess body odor
* sample axilla with cotton round for 3rd party odor assessment
* sample axilla with a swab for skin microbiome analysis via qPCR
* self assess skin irritation